ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Sakar Healthcare delivered exceptional growth as its oncology segment scales, with EBITDA doubling and margins expanding significantly due to product-mix shifts. Management is pivoting from a non-oncology focus to high-margin oncology formulations and APIs.
Q2FY27 consolidated revenue Rs87.4 Cr (+52% YoY), EBITDA Rs24.4 Cr (28% margin), PAT Rs11.3 Cr (+149%); pitch centres on oncology integration.
Sakar Healthcare reported Q2 FY27 revenue of ₹87.42 Cr and PAT of ₹11.31 Cr, up 149% YoY. EBITDA rose 114% to ₹24.35 Cr on strong oncology approvals and commercial supply commencement.
Sakar Healthcare Ltd reported revenue from operations of ₹87.4 Cr (+51.7% YoY) and net profit of ₹11.3 Cr (+151.1% YoY) for Q2 FY27.
Sakar Healthcare has scheduled a board meeting for October 23, 2026, to approve its unaudited quarterly financial results for the period ended September 2026.
Sakar Healthcare says its oncology export model is expanding, with 22 Marketing Authorizations granted and commercial supply starting from its EU GMP site. No monetary value stated.
Sakar Healthcare Limited appointed M/s. Kashyap R. Mehta & Partners as the company's Secretarial Auditors for a five-year term, effective September 22, 2026, following shareholder approval at the AGM.
Sakar Healthcare's 22nd AGM was held on September 22, 2026, adopting audited financials and re-appointing a director. Routine resolutions were passed including secretarial auditor appointment.
Sakar Healthcare Limited received 14 oncology product approvals in the EU, UK, and Canada. These approvals for licensed-out products and site variations will drive top-line sales growth.
Sakar Healthcare Limited submitted its 22nd Annual General Meeting notice and the Annual Report for FY 2025-26. The meeting is scheduled for September 22, 2026.